New Molecule SLAMF6 Identified as T-Cell Brake in Cancer Immunotherapy
Cancer researchers have identified a molecule, SLAMF6, located on the surface of immune cells, which prevents T cells from effectively attacking tumors. A team, led by Dr. André Veillette at Université de Montréal and the Montreal Clinical Research Institute (IRCM), developed a method to neutralize SLAMF6 in mice. These significant findings were published in Nature on February 11, 2026.
Understanding the SLAMF6 Mechanism
Studies conducted by Veillette and his team demonstrated that SLAMF6 operates as an internal brake directly on T cells, without requiring interaction with tumors. This unique self-activation mechanism has been observed to weaken T cell attack capacity, reduce the production of robust T cells, and accelerate immune exhaustion, which can ultimately render T cells ineffective against cancer.
Comparison to Existing Immunotherapies
Current immunotherapies, such as PD1 or PDL1 inhibitors, primarily aim to release constraints that tumors place on the immune system. However, a significant portion of patients do not respond to these treatments or eventually stop responding, highlighting a critical unmet need in cancer treatment.
Development of Novel Antibodies
Veillette's team successfully developed new monoclonal antibodies specifically designed to prevent SLAMF6 from interacting with itself. Observations from the application of these antibodies revealed several promising effects:
- Increased activation of human T cells.
- Higher numbers of resilient immune cells.
- Reduced instances of exhausted T cells.
- Strong anti-tumor responses in mice.
These new antibodies are considered candidates for a new generation of anti-cancer immunotherapies, potentially offering an option for patients who do not respond to PD1 or PDL1 treatments.
Future Implications
The researchers suggest that these new antibodies demonstrated superior performance compared to currently available tools targeting SLAMF6. They are considered promising candidates for a new generation of anti-cancer immunotherapies, potentially offering a vital option for patients who do not respond to existing PD1 or PDL1 treatments. The antibodies could be used either alone or in combination with other immune-stimulating therapies to enhance their effectiveness.
Next Steps Towards Clinical Application
Dr. Veillette's team plans to advance these newly developed antibodies to early-phase clinical trials. The primary goal is to assess their safety and effectiveness in individuals with various solid tumors or blood cancers, moving closer to offering a new therapeutic option to patients.